BuproprionSR — Competitive Intelligence Brief

BuproprionSR (BuproprionSR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor (NDRI). Area: Psychiatry / Mental Health.

marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET) and dopamine transporter (DAT) Psychiatry / Mental Health Small molecule

Target snapshot

BuproprionSR (BuproprionSR) — National Institute of Mental Health (NIMH). Bupropion SR is a norepinephrine-dopamine reuptake inhibitor that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BuproprionSR TARGET	BuproprionSR	National Institute of Mental Health (NIMH)	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
bupropion extra long (XL)	bupropion extra long (XL)	New York State Psychiatric Institute	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET), dopamine transporter (DAT)
Active bupropion, No counseling	Active bupropion, No counseling	University of Wisconsin, Madison	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
Bupropion Hydrochloride Controlled-release	Bupropion Hydrochloride Controlled-release	University of Rochester NCORP Research Base	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
generic bupropion	generic bupropion	University of Michigan	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET); Dopamine transporter (DAT)
Active bupropion-Placebo gum	Active bupropion-Placebo gum	University of Wisconsin, Madison	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
Switch to bupropion	Switch to bupropion	Centre for Addiction and Mental Health	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET); Dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor (NDRI) class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Massachusetts General Hospital · 1 drug in this class
3. National Institute of Mental Health (NIMH) · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. University of Michigan · 1 drug in this class
6. University of Rochester NCORP Research Base · 1 drug in this class
7. University of Texas Southwestern Medical Center · 1 drug in this class
8. Centre for Addiction and Mental Health · 1 drug in this class
9. Washington University School of Medicine · 1 drug in this class